54
Participants
Start Date
October 19, 2021
Primary Completion Date
March 31, 2024
Study Completion Date
June 1, 2024
QLF31907
In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.
RECRUITING
Sichuan Cancer Hospital, Chengdu
Qilu Pharmaceutical Co., Ltd.
INDUSTRY